MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+

MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+

Bibliographic Details
Main Authors: F. Barata, H. Queiroga, E. Teixeira, M.T. Almodovar, B. Parente, M. Soares
Format: Article
Language:English
Published: Elsevier 2016-09-01
Series:Revista Portuguesa de Pneumologia (English Edition)
Online Access:http://www.sciencedirect.com/science/article/pii/S2173511516300148

Internet

http://www.sciencedirect.com/science/article/pii/S2173511516300148

Similar Items